Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.55 |
| ▸ | CA2 | P00918 | 8/20 | 0.55 |
| ▸ | CA4 | P22748 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 6/20 | 0.38 |
| ▸ | CA9 | Q16790 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.30 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20919779 | 0.95 | CA1 (0.60) | CA1CA2CA4TSHRATM | |
| SCHEMBL2794015 | 0.95 | — | — | |
| SCHEMBL36487 | 0.95 | CA1 (0.60) | CA1CA2CA4TSHRATM | |
| SCHEMBL27428074 | 0.90 | CA1 (0.55) | CA1CA2CA4TSHRATM | |
| SCHEMBL27955150 | 0.90 | CA1 (0.55) | CA1CA2CA4TSHRATM | |
| Zinc Ion SCHEMBL28323377 | 0.90 | CA1 (0.55) | CA1CA2CA4TSHRATM | |
| SCHEMBL28280273 | 0.90 | CA1 (0.55) | CA1CA2CA4TSHRATM | |
| SCHEMBL8091291 | 0.90 | CA1 (0.55) | CA1CA2CA4TSHRATM | |
| SCHEMBL29742330 | 0.89 | CA1 (0.67) | CA1CA2CA4TSHRATM | |
| SCHEMBL451236 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309680-B2 | Molybdenum-sulfur additives | INFINEUM INTERNATIONAL LIMITED (GB) | 2007-12-18 | — | — | US | disclosed |
| EP-1382659-B1 | Process for making molybdenum-sulfur additives containing little unreacted sulfur and additives obtained by the process | INFINEUM INT LTD (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-6953771-B2 | Lubricant compositions | INFINEON INTERNATIONAL LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20040132627-A1 | Molybdenum-sulfur additives | INFINEUM INTERNATIONAL LIMITED (GB) | 2004-07-08 | — | — | US | disclosed |
| EP-1382659-A1 | Process for making molybdenum-sulfur additives containing little unreacted sulfur | Infineum International Limited (GB) | 2004-01-21 | — | — | EP | disclosed |
| US-20030224951-A1 | Lubricant compositions | INFINEUM INTERNATIONAL LIMITED (GB) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132627-A1 | Molybdenum-sulfur additives | MSRB3, MSH2, SMO | CA1 3326/4885CA2 4481/4885CA4 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.